Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.23)
# 473
Out of 5,042 analysts
141
Total ratings
53.54%
Success rate
14.24%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Initiates: Overweight | $135 | $93.39 | +44.56% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $2.23 | +348.43% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $49.15 | +32.25% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $43.67 | +71.74% | 5 | Sep 8, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Overweight | n/a | $15.96 | - | 3 | Sep 8, 2025 | |
| SEPN Septerna | Reiterates: Overweight | $25 | $21.67 | +15.37% | 4 | Sep 5, 2025 | |
| CABA Cabaletta Bio | Reiterates: Overweight | $15 | $2.47 | +507.29% | 2 | Sep 5, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $10 → $8 | $3.85 | +107.79% | 7 | Aug 8, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $54.26 | +75.08% | 12 | Jul 29, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $25 | $10.51 | +137.87% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $6.28 | -4.46% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $202.00 | +38.61% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $10.70 | +367.29% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $5.41 | +269.69% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $186.13 | +15.51% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.21 | +126.24% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $24.90 | +703.21% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $47.98 | -47.89% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.69 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $9.11 | +229.31% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.34 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.50 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $40.99 | +119.57% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.37 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $159.66 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $38.00 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.22 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.21 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $84.68 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.61 | +2,359.02% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $40.76 | +59.47% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $70.02 | -14.31% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $5.81 | -13.94% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $2.38 | +362.18% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $144.00 | -9.72% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $577.95 | +31.50% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $17.74 | -15.45% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $7.76 | +608.76% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.01 | +1,392.54% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.46 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $13.03 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $421.50 | -40.69% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $91.28 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $70.86 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $4.65 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $61.01 | -63.94% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.25 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $54.48 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $227.99 | -58.33% | 1 | Aug 17, 2017 |
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $93.39
Upside: +44.56%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $2.23
Upside: +348.43%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $49.15
Upside: +32.25%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $43.67
Upside: +71.74%
Denali Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.96
Upside: -
Septerna
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $21.67
Upside: +15.37%
Cabaletta Bio
Sep 5, 2025
Reiterates: Overweight
Price Target: $15
Current: $2.47
Upside: +507.29%
Rocket Pharmaceuticals
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.85
Upside: +107.79%
BridgeBio Pharma
Jul 29, 2025
Reiterates: Overweight
Price Target: $95
Current: $54.26
Upside: +75.08%
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $10.51
Upside: +137.87%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $6.28
Upside: -4.46%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $202.00
Upside: +38.61%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $10.70
Upside: +367.29%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $5.41
Upside: +269.69%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $186.13
Upside: +15.51%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.21
Upside: +126.24%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $24.90
Upside: +703.21%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $47.98
Upside: -47.89%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.69
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $9.11
Upside: +229.31%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.34
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.50
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $40.99
Upside: +119.57%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.37
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $159.66
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.22
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.21
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $84.68
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.61
Upside: +2,359.02%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $40.76
Upside: +59.47%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $70.02
Upside: -14.31%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $5.81
Upside: -13.94%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $2.38
Upside: +362.18%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $144.00
Upside: -9.72%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $577.95
Upside: +31.50%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $17.74
Upside: -15.45%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $7.76
Upside: +608.76%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.01
Upside: +1,392.54%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.46
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $13.03
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $421.50
Upside: -40.69%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $91.28
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $70.86
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $4.65
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $61.01
Upside: -63.94%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $14.25
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $54.48
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $227.99
Upside: -58.33%